Specific Blood Test Diagnoses Early Onset Kidney Failure
By LabMedica International staff writers Posted on 16 Sep 2014 |
A new and dedicated reagent for the measurement of cystatin C on a portable centrifuge-method clinical chemistry analyzer has been released.
The blood test will support the diagnosis and treatment of early onset kidney failure within clinics where the fully automatic, simple and fast measurement of cystatin C can be used in clinics to aid in rapid testing.
Cystatin C is an important indicator of kidney function. Its utility as an accurate diagnostic marker of diabetic nephropathy, immunoglobulin A (IgA) nephropathy, other types of chronic kidney disease (CKD) and early onset kidney damage is well documented.
In the past, serum creatinine has been used as test for kidney function but this is subject to influence from diet, muscle mass, and exercise. In contrast, cystatin C is not affected by these factors and rises in concentration within blood in line with even minor decreases in kidney function. This allows it to be used for the diagnosis of early onset kidney failure which serum creatinine cannot detect.
The SPOTCHEM Banalyst CysC (Cystatin C) from ARKRAY Inc. (Kyoto, Japan) is an in vitro diagnostic product for the testing of kidney failure. It is used together with whole blood or plasma samples on the SPOTCHEM Banalyst SI-3610, which is being sold through ARKRAY Inc. The SPOTCHEM Banalyst SI-3610 uses Micro Total Analysis Systems (µ-TAS) technology to offer high precision measurement in a compact test system. The µ-TAS analysis system uses a microprocessed chip to include flow channels and reactions which then allows separation of blood cells, reagent mixing and other processes in a short space of time. CysC is the fourth reagent in the series joining glycosylated hemoglobin (HbA1c), C-reactive protein (CRP) and other diabetes and infectious diseases biomarkers.
Related Links:
ARKRAY Inc.
The blood test will support the diagnosis and treatment of early onset kidney failure within clinics where the fully automatic, simple and fast measurement of cystatin C can be used in clinics to aid in rapid testing.
Cystatin C is an important indicator of kidney function. Its utility as an accurate diagnostic marker of diabetic nephropathy, immunoglobulin A (IgA) nephropathy, other types of chronic kidney disease (CKD) and early onset kidney damage is well documented.
In the past, serum creatinine has been used as test for kidney function but this is subject to influence from diet, muscle mass, and exercise. In contrast, cystatin C is not affected by these factors and rises in concentration within blood in line with even minor decreases in kidney function. This allows it to be used for the diagnosis of early onset kidney failure which serum creatinine cannot detect.
The SPOTCHEM Banalyst CysC (Cystatin C) from ARKRAY Inc. (Kyoto, Japan) is an in vitro diagnostic product for the testing of kidney failure. It is used together with whole blood or plasma samples on the SPOTCHEM Banalyst SI-3610, which is being sold through ARKRAY Inc. The SPOTCHEM Banalyst SI-3610 uses Micro Total Analysis Systems (µ-TAS) technology to offer high precision measurement in a compact test system. The µ-TAS analysis system uses a microprocessed chip to include flow channels and reactions which then allows separation of blood cells, reagent mixing and other processes in a short space of time. CysC is the fourth reagent in the series joining glycosylated hemoglobin (HbA1c), C-reactive protein (CRP) and other diabetes and infectious diseases biomarkers.
Related Links:
ARKRAY Inc.
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines